Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

On June 1, Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: TROPION-Lung02, TROPION-Lung04, and NeoCOAST-2. These studies ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

Enhertu is a specifically engineered HER2-directed DXd antibody-drug conjugate (ADC) discovered by Daiichi Sankyo DSNKY DSKYF and being jointly developed and commercialized by AstraZeneca and ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

The drug, known in development as datopotamab deruxtecan, or Dato-DXd, will be marketed ... including breast cancer cells. The AstraZeneca/Daiichi Sankyo drug was evaluated in an open-label ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with previously treated, unresectable, or metastatic HR-positive, HER2-negative ...

Still, AstraZeneca and Daiichi Sankyo are optimistic about the use of Datroway to treat some patients with breast and lung cancers. The drug, also called Dato-DXd, is among a group that ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug ... Datroway, also called datopotamab deruxtecan, or Dato-DXd, was approved in Japan for a form ...

AstraZeneca and Daiichi Sankyo won U.S. approval for a novel breast ... The drug, also called Dato-DXd, is among a group that Astra is counting on for peak annual sales of at least $5 billion ...